Influenza A/B Test Development Enters Optimisation Phase

News Release

06:01:2023

for immediate release

Influenza A/B Test Development Enters Optimisation Phase

Rapid in vitro diagnostics specialist, RAPIvD Ltd has announced successful prototype tests in developing a rapid multiplexed influenza A/B lateral flow assay.

The assay has been developed for partner company Gemina Labs, utilising their proprietary immobilisation chemistry platform and has been shown to reliably detect multiple strains of influenza viruses in spiked samples of artificial nasal fluid. It has been developed on a single test strip with no cross-reactivity between A and B strains.

The prototype is being fine-tuned in an optimisation phase prior to transfer to Gemina Labs for preclinical performance evaluation with patient samples.

RAPIvD CEO, Dr Robert Porter said. “Our prototype tests have delivered impressive results and the use of Gemina’s chemistry has been a key factor in developing a multiplexed strip, with high levels of sensitivity and a considerable reduction in the amount of antibody usage compared to conventional chemistry platforms.

“We aim to improve lateral flow technology by developing assays that are more convenient, accurate and affordable and we’re well on the way to achieving those goals for Gemina with this project”.

Ends.